Earnings ·
Pfizer reports Q3 revenue of $16.6B, raises full-year guidance to $62-$64B
PFEPfizer Inc
Pfizer Inc. reported third-quarter 2026 revenues of $16.6 billion, relatively flat year-over-year operationally, with adjusted diluted EPS of $0.87. The company raised its full-year 2026 revenue guidance by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion and narrowed its adjusted diluted EPS guidance to $2.95 to $3.05. Pfizer also appointed Cecile Guegan as Chief Financial Officer, effective November 1, 2026. The company operates in the global biopharmaceutical industry, focusing on the discovery, development, manufacture, marketing, sale and distribution of medicines.